Aurinia Pharmaceuticals Inc (AUPH) Given Average Rating of “Buy” by Analysts
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given an average recommendation of “Buy” by the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.52.
Several research analysts have recently weighed in on AUPH shares. HC Wainwright cut their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 18th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Vetr downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target for the company. in a research note on Monday, July 31st. Finally, Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th.
Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.74 on Friday. The stock has a 50 day moving average of $6.23 and a 200-day moving average of $6.56. Aurinia Pharmaceuticals has a 12 month low of $1.93 and a 12 month high of $10.54. The company’s market cap is $562.69 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Equities analysts forecast that Aurinia Pharmaceuticals will post ($1.00) earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Aurinia Pharmaceuticals by 8.6% in the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the period. Jane Street Group LLC bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth about $155,000. Cutler Capital Management LLC bought a new position in Aurinia Pharmaceuticals in the 2nd quarter worth about $184,000. Investment Centers of America Inc. bought a new position in Aurinia Pharmaceuticals in the 2nd quarter worth about $184,000. Finally, Two Sigma Securities LLC bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth about $240,000. Institutional investors and hedge funds own 27.83% of the company’s stock.
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/09/aurinia-pharmaceuticals-inc-auph-given-average-rating-of-buy-by-analysts-2.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.